- Home
- OGI vs CRVS Comparison
OGI vs CRVS Comparison
Compare OGI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- CRVS
- Stock Information
- Founded
- OGI 2013
- CRVS 2014
- Country
- OGI Canada
- CRVS United States
- Employees
- OGI N/A
- CRVS N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- OGI Health Care
- CRVS Health Care
- Exchange
- OGI Nasdaq
- CRVS Nasdaq
- Market Cap
- OGI 231.9M
- CRVS 459.0M
- IPO Year
- OGI N/A
- CRVS 2016
- Fundamental
- Price
- OGI $1.76
- CRVS $5.74
- Analyst Decision
- OGI
- CRVS Strong Buy
- Analyst Count
- OGI 0
- CRVS 4
- Target Price
- OGI N/A
- CRVS $15.00
- AVG Volume (30 Days)
- OGI 720.5K
- CRVS 551.9K
- Earning Date
- OGI 08-13-2025
- CRVS 11-11-2025
- Dividend Yield
- OGI N/A
- CRVS N/A
- EPS Growth
- OGI N/A
- CRVS N/A
- EPS
- OGI 0.05
- CRVS N/A
- Revenue
- OGI $164,107,753.00
- CRVS N/A
- Revenue This Year
- OGI $58.15
- CRVS N/A
- Revenue Next Year
- OGI $14.60
- CRVS N/A
- P/E Ratio
- OGI $34.64
- CRVS N/A
- Revenue Growth
- OGI 50.01
- CRVS N/A
- 52 Week Low
- OGI $0.85
- CRVS $2.54
- 52 Week High
- OGI $2.00
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- OGI 67.10
- CRVS 55.89
- Support Level
- OGI $1.56
- CRVS $5.64
- Resistance Level
- OGI $1.70
- CRVS $6.09
- Average True Range (ATR)
- OGI 0.07
- CRVS 0.34
- MACD
- OGI 0.00
- CRVS -0.04
- Stochastic Oscillator
- OGI 90.91
- CRVS 45.10
About OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).